BRIEF-Longeveron® Announces Completion Of Enrollment Of Pivotal Phase 2B Clinical Trial

Reuters
Jun 24
BRIEF-Longeveron® Announces Completion Of Enrollment Of Pivotal Phase 2B Clinical Trial

June 24 (Reuters) - Longeveron Inc LGVN.O:

  • LONGEVERON® ANNOUNCES COMPLETION OF ENROLLMENT OF PIVOTAL PHASE 2B CLINICAL TRIAL EVALUATING LAROMESTROCEL AS A TREATMENT FOR HYPOPLASTIC LEFT HEART SYNDROME (HLHS)

  • LONGEVERON INC - TOP-LINE TRIAL RESULTS EXPECTED IN Q3 2026

Source text: ID:nGNXbh8jKB

Further company coverage: LGVN.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10